Savolitinib + Osimertinib — Competitive Intelligence Brief

Savolitinib + Osimertinib (Savolitinib + Osimertinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 Tyrosine kinase inhibitor combination EGFR and MET Oncology Small molecule

Target snapshot

Savolitinib + Osimertinib (Savolitinib + Osimertinib) — Hutchison Medipharma Limited. Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Savolitinib + Osimertinib TARGET	Savolitinib + Osimertinib	Hutchison Medipharma Limited	phase 3	Tyrosine kinase inhibitor combination	EGFR and MET
Amivantamab Intravenous	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Tislelizumab and nintedanib	Tislelizumab and nintedanib	The Affiliated Hospital of Qingdao University	marketed	PD-1 inhibitor + tyrosine kinase inhibitor combination	PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
Mercaptopurine, Imatinib	Mercaptopurine, Imatinib	St. Jude Children's Research Hospital	phase 3	Purine analog antimetabolite and tyrosine kinase inhibitor combination	Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)
Camrelizumab and Apatinib	Camrelizumab and Apatinib	Chinese Academy of Medical Sciences	phase 3	PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination	PD-1 (camrelizumab); VEGFR2 (apatinib)
Combination PD-1/PD-L1 ICI + VEGFR-TKI	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor combination class)

1. Dong Wha Pharmaceutical Co. Ltd. · 1 drug in this class
2. Hutchison Medipharma Limited · 1 drug in this class